46 news items
Page 2 of 3
9w6jdtm0yo1m9u9zksw2cq8yddu3h201kre9aflo7zzcexjfhuas
BMY
16 May 24
Following four years of continuous Sotyktu treatment, clinical response was maintained in more
yj0g6g0yicr2wl5hbrci7dlsxzrhbq07gzl8gfouivlf7518draarnownmh
BMY
16 May 24
four years of continuous Sotyktu treatment, clinical response was maintained in more than seven out of 10
opvbhm8wla2hefh6rr9kr3uc
BMY
15 May 24
with median duration of response not reached and the majority (77.1%) of responders in ongoing response at 18 months
i4rsjwov hzyzbtp7
BMY
10 May 24
overall survival (OS) across the study arms, PFS by RECIST 1.1 per BICR across the study arms, as well as objective response rate (ORR), time
soqhigiprie1b7r0phl johiq8b47yjihr4d40wls
BMY
29 Apr 24
, it will deploy DECODE to monitor immune responses to the tolerizing vaccines in patients during clinical development to provide key insights
nzvyrairf5xvnplgq84y0nfu0y5o8or5b3kgkcwjta7
BMY
26 Apr 24
', or 'Lower' their stance, it signifies their response to recent developments related to Bristol-Myers Squibb. This offers insight into analysts' perspectives
sa4cma34fcyd3cek02tnj7h4yptlyp8
BMY
26 Apr 24
of care for decades but the durability of response to chemotherapy alone is poor and once a patient progresses, treatment options become increasingly
nqk4c0 3hgzltjb7
BMY
25 Apr 24
response
s759pisy0uz5tdsmgnq10r5x2
AGEN
BMY
12 Apr 24
response rate (ORR) was observed after a median follow up of 13.6 months at the data cutoff of March 1, 2024.
The median duration
q5zb6eu82i
BMY
JNJ
MRK
10 Apr 24
continues to build its heart business.
Johnson & Johnson is focusing on enhancing its cardiovascular health business in response to its
6zj7a022jdxjcna3
BMY
8 Apr 24
.
With a median follow-up of 11.9 months in 94 patients, Krazati plus cetuximab demonstrated an objective response rate, the primary endpoint, of 34%, median
efk33wmoaly cu6
BMY
TSVT
5 Apr 24
showed a significant improvement in overall response rates (p<0.0001) with the majority (71%) of patients treated
zttmhsnc97nw21evgk
BMY
IRON
VERV
4 Apr 24
with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. It is also indicated for the treatment
du3vkf8tp9wz7lznf45ub0ej8taunwdbvzog3jophihlr1
BMY
LAB
3 Apr 24
on the development of these new tools that will accelerate insights into disease response," says Michael Egholm, President and Chief Executive Officer
1mr5alkzruooipxga7xbi81hdcyg53
BMY
2 Apr 24
.
"In the treatment of lower-risk MDS, few patients experience a lasting response to erythroid stimulating agents, leaving a critical need for more